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Abstract. Duchenne muscular dystrophy is due to genetic 
abnormalities in the dystrophin gene and represents one of 
the most frequent genetic childhood diseases. In the X-linked 
muscular dystrophy (mdx) mouse model of dystrophinopathy, 
different subtypes of skeletal muscles are affected to a 
varying degree albeit the same single base substitution within 
exon 23 of the dystrophin gene. Thus, to determine potential 
muscle subtype-specific differences in secondary alterations 
due to a deficiency in dystrophin, in this study, we carried 
out a comparative histological and proteomic survey of mdx 
muscles. We intentionally included the skeletal muscles that 
are often used for studying the pathomechanism of muscular 
dystrophy. Histological examinations revealed a significantly 
higher degree of central nucleation in the soleus and extensor 
digitorum longus muscles compared with the flexor digitorum 
brevis and interosseus muscles. Muscular hypertrophy of 
20-25% was likewise only observed in the soleus and extensor 
digitorum longus muscles from mdx mice, but not in the flexor 
digitorum brevis and interosseus muscles. For proteomic 
analysis, muscle protein extracts were separated by fluores-
cence two-dimensional (2D) gel electrophoresis. Proteins 
with a significant change in their expression were identified 
by mass spectrometry. Proteomic profiling established an 
altered abundance of 24, 17, 19 and 5 protein species in the 
dystrophin-deficient soleus, extensor digitorum longus, flexor 
digitorum brevis and interosseus muscle, res pectively. The key 
proteomic findings were verified by immunoblot analysis. The 
identified proteins are involved in the contraction-relaxation 
cycle, metabolite transport, muscle metabolism and the cellular 
stress response. Thus, histological and proteomic profiling of 
muscle subtypes from mdx mice indicated that distinct skeletal 
muscles are differentially affected by the loss of the membrane 
cytoskeletal protein, dystrophin. Varying degrees of perturbed 
protein expression patterns in the muscle subtypes from mdx 
mice may be due to dissimilar downstream events, including 
differences in muscle structure or compensatory mechanisms 
that counteract pathophysiological processes. The interos-
seus muscle from mdx mice possibly represents a naturally 
protected phenotype.
Introduction
Duchenne muscular dystrophy is the most frequent gender- 
specific genetic disease of the neuromuscular system and is 
characterised by symmetric and highly progressive muscle 
wasting. Degeneration of muscle fibers and subsequent fibrosis 
result in gait disturbance in early childhood followed by the loss 
of ambulation and severe cardiorespiratory complications in 
older children (1). Primary genetic abnormalities in the dystro-
phin gene cause the loss of a crucial membrane cytoskeletal 
protein of 427 kDa that is normally located in the subsarco-
lemmal region of the muscle fibers (2). Although considerable 
progress has been made in the development of genetic and cell-
mediated approaches to eliminate the primary abnormality in 
dystrophinopathies (3), there is still the urgent need to address 
secondary alterations in the highly complex pathology of 
X-linked muscular dystrophy (4,5). One pro mising approach is 
the detailed molecular and cellular analysis of genetic animal 
models of muscular dystrophy and the subsequent evaluation 
of novel substances or treatment strategies in expe rimental 
phenotypes (6). In this respect, the X-linked muscular dystrophy 
(mdx) mouse is the most widely used animal model of Duchenne 
muscular dystrophy for studying secondary effects due to the 
reduction of the dystrophin-glycoprotein complex (7-10).
A point mutation in exon 23 induces a loss in the expres-
sion of the dystrophin isoform, Dp427, in muscle tissue from 
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mdx mice (11). However, the same primary abnormality does 
not cause identical downstream effects in different muscles, 
making the mdx mouse an extremely interesting model 
system for studying secondary effects in dystrophinopathy. 
As previously reported, whilst the extraocular and laryngeal 
muscles are only mildly affected (12-14), the hind limb 
muscles exhibit a moderate dystrophic phenotype (15-17) 
and the diaphragm muscle is severely degenerated (18-20). 
The comparative analysis of differentially affected muscles 
may thus be helpful in determining how a single mutation in 
a muscle-specific gene can result in such a variety of patho-
physiological phenotypes.
Over the last few years, mass spectrometry (MS)-based 
proteomics has been successfully applied to investigate normal 
and pathologically altered skeletal muscle tissue (21-23), 
establishing a variety of novel proteomic biomarkers of neuro-
muscular disorders (24). This has included the large-scale 
proteomic profiling of various muscle tissues from mdx mice 
and has revealed differential degrees of perturbed protein 
expression patterns in dystrophin-deficient fibers (25). Gel 
electrophoresis-based proteomics has been applied to evaluate 
dystrophic muscles from mdx mice focusing on the cytosolic 
fraction from 1- to 6-month-old hind limb muscle covering 
an isoelectric point (pI) range of 4-7 and using Coomassie 
and silver staining (26,27), crude extracts from gastrocnemius 
muscle from 9-week-old hind limb tissue covering a pI range 
of 3-10 and using Stains-All labelling (28), crude extracts from 
9-week-old diaphragm tissue covering a pI range of 3-10 and 
using hot Coomassie staining (29), crude extracts from 9-week-
old diaphragm tissue covering a pI range of 3-10 and using 
fluorescence two-dimensional difference in gel electro phoresis 
(2D-DIGE) (30), crude extracts from 10-week-old antisense 
oligomer-treated diaphragm tissue covering a pI range of 3-10 
and using 2D-DIGE (31), extracts from 6-week-old gastrocne-
mius muscle covering a pI range of 3-10 and using 2D-DIGE (32), 
total extracts from 22-month-old diaphragm covering a pI range 
of 3-10 and using fluorescence labelling (33), total extracts from 
22-month-old tibialis anterior muscle covering a pI range of 
3-10 and using fluorescence labelling (34) and crude extracts 
from 9-week-old extraocular muscle covering a pI range of 3-10 
and using fluorescence 2D-DIGE (35). Recently, gel-free in vivo 
SILAC proteomics was carried out with 3-week-old gastroc-
nemius muscle (36). In addition, proteomics has been used to 
evaluate novel protein factors in serum (37,38) and dystrophic 
heart tissue (39-42).
It is to be hoped that the establishment of a detailed 
biomarker signature of X-linked muscular dystrophy 
will improve our understanding of the pathobiochemical 
processes underlying dystrophinopathy. A comprehensive list 
of secondary effects would also be extremely useful for the 
biochemical evaluation of experimental treatments, such as 
stem cell therapy or exon-skipping approaches to ameliorate 
downstream alterations of dystrophin deficiency (4,5). The 
underlying objective of this study was the formation of an mdx 
reference map of differentially affected muscles with the same 
primary abnormality but diverging downstream effects. In 
humans, the equivalent mouse muscle tissue subtypes investi-
gated relate to i) soleus (SOL), a muscle of the back part of the 
lower leg lying just beneath the gastrocnemius that contains 
almost exclusively oxidative fibers; ii) extensor digitorum 
longus (EDL), a muscle located in the lateral part of the front 
of the leg that contains a large portion of glycolytic type 2B 
and 2X fibers; iii) flexor digitorum brevis (FDB), a muscle that 
lies in the middle of the sole of the foot and contains a high 
number of oxidative-glycolytic type 2A fibers; and iv) interos-
seus (INT), muscles of the hand located near the metacarpal 
bones that contain predominantly type 2 fibers (43-46). All 
four muscles have been widely used to investigate alterations 
of muscle structure, function, physiology and biochemistry in 
mdx mice.
However, with respect to routine biological analyses, each 
of these muscle subtypes has strengths and weaknesses. While 
EDL and SOL are well suited to study muscle biochemistry, 
force and fatigue, FDB and INT can be enzymatically disso-
ciated into single fibers. The two latter muscles can quite easily 
be studied on the single fiber level. Thus, many observations 
on Ca2+ influx, subsarcolemmal Ca2+ levels and the function of 
cation channels have been made with INT (9,47,48) and FDB 
(47,49,50) muscles without taking into consideration whether 
these findings can be generalised. Accordingly, we included 
FDB and INT muscle preparations in our proteomic analyses 
to evaluate whether they display similar abnormalities as 
compared to other limb muscles from mdx mice. Proteomics 
revealed an altered expression for 24, 17, 19 and 5 protein 
species in the dystrophic SOL, EDL, FDB and INT muscles, 
respectively. These marked differences in the degree of protein 
perturbation are possibly a result of dissimilar secondary 
processes in the molecular pathogenesis of different subtypes 
of muscles from mdx mice.
Materials and methods
Materials. Immobilised pH gradient strips of pH 3-10, IPG 
buffers and electrophoresis-grade chemicals were obtained 
from Amersham Biosciences/GE Healthcare (Little Chalfont, 
UK). Acrylamide stock solutions were purchased as ultrapure 
protogel mixtures from National Diagnostics (Atlanta, GA, 
USA). Fluorescent ruthenium II bathophenathroline disul-
fonate for the production of RuBPs dye was from Reagecon 
Diagnostics Ltd. (Shannon, Ireland). Coomassie blue dye, 
Laemmli-type gel buffers and protein molecular mass stan-
dards, as well as Bradford reagent for protein quantification 
were from Bio-Rad Laboratories (Hemel-Hempstead, UK). 
Chemiluminescence substrate and protease inhibitors were 
purchased from Roche Diagnostics (Mannheim, Germany). 
For the reproducible generation of peptide populations from 
2D spots by in-gel digestion, sequencing grade-modified 
trypsin was obtained from Promega Corp. (Madison, WI, 
USA). LC-MS CHROMASOLV® water and formic acid were 
from Fluka (Dorset, UK). Nitrocellulose transfer stacks were 
obtained from Invitrogen Life Technologies (Carlsbad, CA, 
USA). X-ray film was from Fuji Photo Film (Tokyo, Japan). 
Antibodies were purchased from Abcam (Cambridge, UK; 
ab77232 to myoglobin, ab9465 to actinin, ab11427 to parv-
albumin, ab6588 to collagen, ab75223 to phosphoglycerate 
kinase, ab14226 to serpina and ab13496 to αB-crystallin) 
and Sigma (Dorset, UK; L9393 to laminin). All secondary 
antibodies were from Chemicon International (Temecula, 
CA, USA). Ponceau S red staining solution, DNase-I and all 
general chemicals were obtained from Sigma.
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Genetic mouse model of Duchenne muscular dystrophy. In 
analogy to patients suffering from X-linked muscular dystrophy, 
the mutant mdx mouse is missing the Dp427 isoform of the 
membrane cytoskeletal protein, dystrophin (8), and exhibits a 
drastic reduction in dystrophin-associated glycoproteins (51). 
The genetic basis of this abnormality is a single base substitu-
tion within exon 23 of the dystrophin gene (11). SOL, EDL, 
FDB and INT muscles from 3-month-old mdx mice (C57BL/10 
ScSn Dmdy (mdx)/J) and age-matched wild-type (WT) mice 
(C57BL/10 ScSn) were obtained from the BioResource Unit 
of the University of Greifswald, Greifswald, Germany (52). 
The mouse strains were originally obtained from the Jackson 
Laboratory (Bar Harbor, ME, USA). Mice were kept under 
standard conditions and all procedures were performed in 
accordance with the German guidelines on the use of animals 
for scientific experiments (approval by District Veterinary 
Office, Anklam, Germany). The animals were sacrificed by 
cervical dislocation and muscle tissues were immediately 
removed. The samples used for proteomic analysis were quick-
frozen in liquid nitrogen and those for histological staining 
were frozen in petroleum ether at -90°C.
Histological Analyses. Frozen muscle tissue was cut into 7 µm 
cross sections using a cryostat (Frigocut 2800N, Leica). The 
sections were stained with hematoxylin and eosin (H&E) 
according to standard protocols. Central and peripheral nuclei 
of muscle fibers were counted. For evaluation, digital micro-
scopic recordings with a magnification of x200, were analysed. 
Muscles specimens from six mice per strain were investigated.
Proteomic analysis. For the proteomic analysis of mdx tissue, 
muscle specimens were shipped to Ireland on dry ice and 
stored at -80˚C prior to usage. In order to obtain sufficient 
protein extracts, 30 dystrophic and 30 normal specimens from 
each skeletal muscle investigated were pulverised by grinding 
the tissue pieces in liquid nitrogen using a mortar and pestle. 
The ground muscle powder was solubilised in lysis buffer with 
the ratio of 100 mg wet weight/ml lysis buffer [7 M urea, 2 M 
thiourea, 4% CHAPS, 2% IPG buffer pH 3-10, 2% (w/v) DTT]. 
To prevent excess protein degradation, the lysis buffer was 
supplemented with a freshly prepared protease inhibitor cock-
tail as previously descrbied (29). Following gentle rocking for 
60 min, the suspensions were centrifuged at 4˚C for 20 min at 
15,000 x g (35) and the protein concentration was determined 
as previously described (53).
2D gel electrophoresis. The high-resolution 2D gel electropho-
retic separation of the urea-soluble protein complement from 
normal vs. dystrophic SOL, EDL, FDB and INT muscle tissue 
was carried out using a total protein amount of 500 µg per 
analytical slab gel. Using a reswelling tray from Amersham 
Biosciences/GE Healthcare, IPG strips of pH 3-10 were rehy-
drated for 12 h with 0.45 ml of a rehydration buffer containing 
7 M urea, 2 M thiourea, 65 mM CHAPS, 10 mg/ml DTT, and 
500 µg of muscle protein sample, as well as 1% (v/v) ampho-
lytes pH 3-10. As a tracking dye, the buffer was complemented 
with 0.05% (w/v) bromophenol blue. Following placement of 
the first-dimension strips (24 cm in length) gel-side up onto the 
Ettan IPGphor manifold and coverage with 108 ml of dry-strip 
cover fluid, gels were run on the IPGphor IEF system with 
the following isoelectric focusing running conditions: 80 V for 
4 h, 100 V for 2 h, 500 V for 1.5 h, 1,000 V for 1 h, 2,000 V 
for 1 h, 4,000 V for 1 h, 6,000 V for 2 h, 8,000 V for 2.5 h, 
and 500 V holding step; and 8,000 V for 1 h if strips had been 
at the 500 V holding step. Gel strips were then equilibrated 
for 30 min; using during the first 15 min of equilibration a 
buffer system with 100 mM dithiothreitol and during the 
last 15 min of incubation an equilibration buffer containing 
0.25 M iodoacetamide. The second dimension separation was 
carried out with an Ettan DALTtwelve system from Amersham 
Biosciences/GE Healthcare using standard 12.5% (w/v) slab 
gels. Following washing in sodium dodecyl sulfate-containing 
running buffer, isoelectric focusing strips were placed on top 
of second dimension gels and held in place with a 1% (w/v) 
agarose sealing gel. The comparative proteomic profiling of 
SOL, EDL, FDB and INT muscles required the employment of 
32 slab gels, which were run at 0.5 W/gel for 60 min and then 
15 W/gel was used until the blue dye front had disappeared 
from the bottom of the gel.
Post-electrophoretic protein labelling with fluorescent ruthe-
nium II tris(bathophenanthroline disulfonate) (RuBPs) dye. 
The staining of 2D gels was carried out with the fluorescent dye, 
RuBPs, as previously described (54). A stock solution of RuBPs 
dye was prepared as outlined by Rabilloud et al (55). Following 
fixation for 30 min in 30% ethanol and 10% acetic acid, the gels 
were washed three times for 30 min in 20% ethanol and then 
stained for 6 h in 20% (v/v) ethanol containing 2 µM of ruthe-
nium chelate. The gels were re-equili brated twice for 10 min 
in distilled water and destained overnight in 40% ethanol and 
10% acetic acid prior to imaging (41). Fluorescently labelled 
proteins were visuali sed using a Typhoon Trio variable mode 
imager (Amersham Biosciences/GE Healthcare). Gel analysis 
was performed with Progenesis SameSpots analysis software 
from Nonlinear Dynamics (Newcastle upon Tyne, UK) using 
the following parameters: ANOVA p<0.05; n=4; and a power 
value >0.8. The 12.5% (w/v) slab gels used in this study sepa-
rated muscle-associated proteins ranging in molecular mass 
from approximately 15-220 kDa. Proteins in spots with a signif-
icant increase or decrease in abundance (differing between the 
various groups with >2-fold change) were identified by MS.
MS identification of muscle proteins. The mass spectro-
metric identification of proteins of interest was carried out 
with 2D protein spots from Coomassie-stained pick gels, 
following counter-staining of RuBPs-labelled analytical gels. 
Standardised in-gel tryptic digestion was used for the genera-
tion of representative peptide mixtures (54). The excision of 
gel plugs, washing and destaining of protein spots and treat-
ment with trypsin were performed by a previously optimised 
method (56,57). Trypsin-generated peptides were harvested 
by removing supernatants from digested gel plugs after 
centrifugation. Further recovery was achieved by the addi-
tion of 30% acetonitrile/0.2% trifluoroacetic acid to the gel 
plugs for 10 min at 37˚C with gentle agitation. The resulting 
supernatants were pooled with the initially recovered peptides 
following trypsin digestion (58). Peptide samples were dried 
through vacuum centrifugation and concentrated fractions 
were suspended in MS-grade distilled water and 0.1% formic 
acid, spun down through spin filters and added to LC-MS vials 
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for identification by ion trap LC-MS analysis. Electrospray 
io nization LC-MS/MS analysis was carried out as previously 
described (56) using a Model 6340 Ion Trap/LC-MS apparatus 
from Agilent Technologies (Santa Clara, CA, USA). The sepa-
ration of peptides was performed with a nanoflow Agilent 1200 
series system equipped with a Zorbax 300SB-C18 analytical 
reversed phase column using HPLC-Chip technology. Mobile 
phases used were A, 0.1% formic acid; B, 50% acetonitrile 
and 0.1% formic acid. Samples were loaded into the enrich-
ment part of the chip at a capillary flow rate set to 4 µl/min 
with a mixture of solvent A and solvent B at a ratio of 19:1. 
Tryptic digests were eluted with a linear gradient of 5-70% 
solvent B over 6 min, 70-100% solvent B over 1 min, 100-5% 
over 1 min (56). A 5-min post-time of solvent A was used to 
remove any potential carry-over. The capillary voltage was 
set to 2,000 V. The flow and temperature of the drying gas 
were 4 l/min and 300˚C, respectively. Database searches were 
carried out with Mascot MS/MS ion search (Matrix Science 
Ltd., London, UK; NCBI database, release 20100212). All 
searches used ‘Mus musculus’ as taxonomic category and 
the following parameters: i) two missed cleavages by trypsin; 
ii) mass tolerance of precursor ions ±2.5 kDa and product ions 
±0.7 kDa; iii) carboxymethylated cysteins fixed modification; 
iv) oxidation of methionine as variable modification; and v) at 
least two matched distinct peptides. Mascot scores >50 are 
listed in Tables I-IV. All pI-values and molecular masses of 
identified proteins were compared to the relative position of 
their corresponding 2D-spots on analytical slab gels.
Verification of key proteomic findings by immunoblot 
analysis. In order to verify potential alterations in the concen-
tration of select muscle-associated proteins and to confirm 
the findings from the comparative proteomic profiling of 
dystrophic muscle specimens from mdx mice, immunoblotting 
of proteins of interest was carried out. Following the electro-
phoretic transfer of proteins onto nitrocellulose membranes, 
the sheets were blocked in a fat-free milk protein solution for 
1 h and then incubated overnight with gentle agitation with 
primary antibody, sufficiently diluted in blocking solution 
containing 5% (w/v) milk powder in phosphate buffered saline 
[PBS; 0.9% (w/v) NaCl, 50 mM sodium phosphate, pH 7.4] as 
previously described (56). Following washing with blocking 
solution twice for 10 min, the blots were incubated for 1 h 
with secondary peroxidase-conjugated antibodies, diluted in 
blocking solution. Antibody-decorated bands in washed blots 
were visualised by the enhanced chemiluminescence method 
following the manufacturer's recommendations. Densitometric 
scanning of immunoblots was performed on a Computing 
Densitometer 300S (Molecular Dynamics, Sunnyvale, CA, 
USA) with ImageQuant tools V3.0 software (29).
Results
Histological profiling of skeletal muscle tissue from mdx 
mice. The histological examination of cross sections from 
the SOL, EDL, FDB and INT muscles revealed central nucle-
ation in all tested types of skeletal muscle from mdx mice 
(Fig. 1B, D, F and H). In addition, the muscles revealed fiber 
size variations and the occurrence of small, rounded fibers. As 
expected, central nuclei were rarely observed in the muscle 
fibers from WT mice (Fig. 1A, C, E and G). Quantitative 
evaluation of central nucleation revealed a significantly lower 
degree of nucleation in the FDB and INT muscles compared 
with the SOL and EDL muscles (Fig. 2A). It is well known that 
dystrophin-deficient muscle can develop a mild hypertrophy, 
at least at certain stages. While the body weight of mdx mice 
was almost identical to that of the WT mice (data not shown), 
the mass of the EDL and SOL muscles from the mdx animals 
was on average 20-25% higher. By contrast, no evidence of 
hypertrophy was observerd for the two smaller muscles, FDB 
and INT (Fig. 2B).
Comparative proteomic profiling of skeletal muscle tissue from 
mdx mice. High-resolution 2D gel electrophoresis was used to 
separate the urea-soluble portion of the assessable proteome 
from normal vs. dystrophic SOL, EDL, FDB and INT muscle 
tissues. Post-electrophoretic labelling of 2D protein spots was 
achieved with the fluorescent dye, RuBPs, and protein species 
with a significantly altered abundance in dystrophic prepara-
tions were determined by densitometric scanning. MS was then 
employed to identify the muscle-associated proteins of interest. 
Fig. 3 summarizes analytical gels used to evaluate whether 
marked differences exist in the degree of protein perturbation 
between different subtypes of dystrophin-deficient skeletal 
muscles. Individual panels A-D show four biological repeats 
of gel electrophoretic analyses of normal (SOL WT 1-4) vs. 
dystrophic (SOL MDX 1-4) SOL, normal (EDL WT 1-4) vs. 
dystrophic (EDL MDX 1-4) EDL, normal (FDB WT 1-4) vs. 
dystrophic (FDB MDX 1-4) FDB and normal (INT WT 1-4) vs. 
dystrophic (INT MDX 1-4) INT muscle tissues, respectively. 
Since the overall 2D protein spot patterns of WT vs. dystro-
phic specimens (MDX) were relatively comparable, a detailed 
densitometric analysis for the determination of significant 
differences in muscle-associated proteins was carried out. With 
the help of a Typhoon Trio variable imager and Progenesis 2D 
analysis software, skeletal muscle proteomes from mdx mice 
were compared. Figs. 4-7 represent master gels of the SOL, 
EDL, FDB and INT muscles, respectively.
Proteomic analysis of SOL muscle from mdx mice. A fluo-
rescent RuBPs-labelled master gel of mdx SOL muscle is 
shown in Fig. 4. An altered expression was observed for 
24 protein species in the dystrophin-deficient SOL prepara-
tions. Proteins with significant changes in expression levels 
are marked by circles and are numbered 1-24 in the master 
gel. The mass spectrometric identification of these muscle 
proteins with changes in expression is listed in Table I. This 
table includes the names of the identified muscle-associated 
proteins, their international accession number, pI-values, 
their relative molecular masses, number of matched peptide 
sequences, percentage sequence coverage, Mascot scores and 
fold change of individual proteins affected in the SOL muscle 
from mdx mice. Protein species with an altered expression 
in the SOL muscle ranged in molecular mass from 17 kDa 
(myoglobin) to 127 kDa (myosin binding protein) and covered 
a pI-range from pI 4.7 (myosin light chain) to 8.9 (malate 
dehydrogenase). As listed in Fig. 4 and Table I, proteomic 
profiling suggests a dystrophy-associated increase in various 
myosin light chains (MLCs), including MLC1/3, MLC2 and 
MLC3 (spots 1, 5, 11, 17 and 19), cadherin (spot 2), aldolase 
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(spot 3), αB-crystallin (spots 4, 9 and 14), troponin C (TnC) 
(spot 6), glutathione transferase (spot 7), 14-3-3 protein 
(spots 8 and 15), collagen (spot 10) phosphatase (spot 12), 
ferritin (spot 13), slow myosin binding protein C (MyBP-C) 
(spot 16) and peroxiredoxin (spot 18). By contrast, decreased 
concentrations were observed in the case of tumor metastatic 
process-associated protein NM23 (spot 20), myoglobin 
(spot 21), the ATP synthase Atp5b (spot 22), creatine kinase 
(spot 23) and malate dehydroge nase (spot 24).
Proteomic analysis of EDL muscle from mdx mice. A master 
gel of dystrophic EDL muscle is presented in Fig. 5, illustrating 
an altered expression in 17 protein species. The mass spec-
trometric identification of these muscle-associated proteins 
is listed in Table II. Proteins with an altered density in EDL 
muscle ranged in molecular mass from 17 kDa (myoglobin) to 
224 kDa (myosin) and covered a pI-range from pI 5.2 (actin) to 
pI 9.0 [troponin T (TnT)]. MS-based proteomics revealed an 
increase in fast troponin TnT (spots 1 and 9), myoglobin (spot 2), 
phosphoglycerate mutase (spots 3 and 15), glyceraldehyde-
3-phosphate dehydrogenase (spot 4), triosephosphate isomerase 
(spot 5), myosin (spot 6), lactate dehydrogenase (spot 7), phos-
phoglycerate kinase (spot 8), creatine kinase (spot 10), malate 
dehydrogenase (spot 11), actin (spot 12), glycogen phosphorylase 
(spot 13) and phosphoglycerate kinase (spot 14). A decreased 
abundance was established for glycogen phosphorylase (spot 16) 
and actinin (spot 17).
Proteomic analysis of FDB muscle from mdx mice. The 
proteomic survey of dystrophic FDB muscle is shown in 
Fig 6. Proteins with an altered expression are marked in the 
master gel and numbered 1-19. Table III lists the mass spec-
trometric identification of these muscle-associated proteins. 
Proteins ranged in molecular mass from 12 kDa (parval-
bumin) to 130 kDa (collagen) and covered a pI-range from 
pI 4.9 (vimentin) to 9.2 (collagen). Mass spectrometric analyses 
revealed an increased concentration in FDB muscle for fast 
troponin I (TpI) (spot 1), serpina 1d protein (spots 2, 6 and 9), 
αB-crystallin (spot 3), vimentin (spot 4), phosphoglycerate 
mutase (spot 5), desmin (spot 7), leukocyte elastase inhibitor A 
(spot 8) and tropomyosin (spot 10). Proteins with a decreased 
abundance in FDB muscle were shown to be the glycolytic 
enzyme aldolase (spots 11, 12, 15, 17 and 18), parvalbumin 
(spots 13 and 16), 14-3-3 protein (spot 14) and collagen (spot 19).
Table I. List of muscle-associated proteins with an altered abundance in the soleus muscle from mdx mice.
   Mascot  Molecular Peptides Sequence  Fold
Spot no. Protein name Accession no. score pI mass (Da) matched coverage (%) change
  1 Myosin light chain 2 (MLC2) AAA39796 401 4.71 18870 9 60 5.0
  2 Cadherin 13 AAH21628 104 4.9 78474 2 4 4.4
  3 Aldolase A, isoform 2 NP031464 136 8.31 39795 17 40 4.3
  4 αB-crystallin NP034094 121 6.76 20056 3 28 4.2
  5 Myosin light chain 3 (MLC3) EDL09001 268 5.03 22523 6 38 3.3
  6 Troponin C, skeletal muscle  NP033420 190 4.07 18156 2 20 3.1
  7 Glutathione S-transferase NP034488 415 7.71 26069 9 42 2.8
  8 14-3-3 Protein γ  NP036611 145 4.8 28519 4 9 2.8
  9 αB-crystallin NP034094 58 6.76 20056 1 14 2.8
10 Collagen α-1 (VI) chain NP034063 224 5.2 109582 13 16 2.6
11 Myosin light chain 2 (MLC2) NP058034 272 4.82 19059 4 31 2.5
12 Mg-dependent phosphatase 1 NP075886 98 6.29 18629 3 29 2.4
13 Ferritin light chain 1 P29391 372 5.66 20848 6 44 2.3
14 αB-crystallin NP034094 141 6.76 20056 13 60 2.3
15 14-3-3 Protein ζ  BAA13421 258 4.7 27911 4 18 2.2
16 Myosin binding protein C, slow  HQ848554 411 5.74 127046 9 10 2.1
17 Myosin light chain 2 (MLC2) NP058034.1 161 4.82 19059 5 44 2.1
18 Peroxiredoxin-1 NP035164 170 8.26 22394 5 24 2.0
19 Myosin light chain 1/3 (MLC1/3) NP067260 514 4.98 20697 11 53 2.0
20 Tumor metastatic process- AAA39826 141 8.44 18846 4 40 -2.0
 associated protein NM23
21 Myoglobin NP038621 161 7.07 17117 2 21 -2.1
22 Atp5b protein  BC037127 488 5.24 56632 7 20 -2.2
23 Creatine kinase M-type  NP031736 97 6.58 43250 2 7 -2.3
24 Malate dehydrogenase  AAA39509 132 8.93 36052 5 22 -4.2
pI, isoelectric point.
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Figure 1. Histological profiling of skeletal muscles from X-linked muscular dystrophy (mdx) mice. Shown are hematoxylin and eosin-stained muscle cross-
sections from wild-type (WT; A, C, E and G) and mdx mice (B, D, F and H). Note the reduced occurrence of central nuclei in the flexor digitorum brevis (FDB) 
and interosseus (INT) muscles, compared with the soleus (SOL) muscle and extensor digitorum longus (EDL) muscle from mdx mice. Muscles were prepared 
from 100-day-old male animals. Scale bar, 20 µm.
Figure 2. Degree of central nucleation and muscle weight of different mdx skeletal muscles. (A) Shown is the graphical presentation of the degree of central 
nucleation in wild-type (WT) vs. dystrophic soleus (SOL), extensor digitorum longus (EDL), flexor digitorum brevis (FDB) and interosseus (INT) muscles 
from X-linked muscular dystrophy (mdx) mice. The fractions of fibers with central nuclei are presented as a percentage (%) for the four muscles (mdx. n=6; 
WT, n=4 independent muscles and animals). In each muscle cross-section approximately 100 fibers were counted and classified. Data from the FDB and INT 
muscles from mdx mice were tested for significant differen ces to those of the SOL and EDL muscles. Statistical tests were performed independently for all 
pairs. (B) The average muscle weight is provided for the four muscles (n=4-6). (A and B) The means ± SD are provided in all cases; asterisks (*) indicate 
significant differences (Mann-Whitney U test; *p<0.05; **p<0.01).
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Proteomic analysis of INT muscle from mdx mice. In contrast 
to the above listed findings of considerable changes in the 
proteomes from dystrophic SOL, EDL and FDB muscle, the 
mass spectrometric analysis of INT muscle revealed only a 
limited number of altered proteins. In the master gel shown in 
Fig. 7, proteins with a change in expression are numbered 1-5. 
Table IV lists the proteomic identification and fold change of 
these proteins in dystrophic INT muscle. An increased expres-
sion level in INT muscle was shown for fast TpI (spots 1 and 2), 
the molecular chaperone αB-crystallin (spot 3) and the 40 kDa 
protein (spot 4). By contrast, the cytosolic Ca2+-binding protein 
parvalbumin was found to be decreased in the INT muscle.
Figure 3. Overview of two-dimensional (2D) gel electrophoretic survey of skeletal muscles from X-linked muscular dystrophy (mdx) mice. Shown areRuBPs-
stained gels of total extracts from 3-month-old normal wild-type (WT) vs. dystrophic (MDX) (A) soleus (SOL), (B) extensor digitorum longus (EDL), 
(C) flexor digitorum brevis (FDB) and (D) interosseus (INT) muscles. The 32 gel images contain four biological repeats of each group of normal (wild-type; 
WT 1-4) vs. diseased (MDX 1-4) muscles. Fluorescent images are shown for the pH 3-10 range.
Figure 4. Fluorescence two-dimensional (2D) gel electrophoretic analysis 
of soleus muscle from mdx mice. Shown is a representative RuBPs-labelled 
master gel of crude tissue extracts from soleus muscle from mdx mice. 
Protein spots with an age-related change in expression levels are marked by 
circles and are numbered 1-24. See Table I for the mass spectrometric iden-
tification of individual muscle-associated proteins. The pH-values of the first 
dimension gel system and molecular mass standards of the second dimension 
are indicated on the top and on the left of the panels, respectively.
Figure 5. Fluorescence two-dimensional (2D) gel electrophoretic analysis of 
extensor digitorum longus muscle from mdx mice. Shown is a representative 
RuBPs-labelled master gel of crude tissue extracts from extensor digitorum 
longus muscle from mdx mice. Protein spots with an age-related change in 
expression levels are marked by circles and are numbered 1-17. See Table II 
for the mass spectrometric identification of individual muscle-associated 
proteins. The pH-values of the first dimension gel system and molecular mass 
standards of the second dimension are indica ted on the top and on the left of 
the panels, respectively.
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Table II. List of muscle-associated proteins with an altered abundance in the extensor digitorum longus muscle from mdx mice.
   Mascot  Molecular Peptides Sequence  Fold
Spot no. Protein name Accession no. score pI mass (Da) matched coverage (%) change
  1 Troponin T, fast skeletal muscle AAB39743 66 9.01 29358 2 11 3.8
  2 Myoglobin NP038621 547 7.07 17117 11 68 3.7
  3 Phosphoglycerate mutase 2 NP061358 484 8.65 28983 11 49 3.4
  4 Glyceraldehyde-3-phosphate  AAH85315 347 7.59 36099 7 30 3.0
 dehydrogenase
  5 Triosephosphate isomerase  AAB48543 90 5.62 22724 4 22 2.6
  6 Myosin-1 NP109604 774 5.60 224131 19 11 2.6
  7 Lactate dehydrogenase B chain  NP032518 775 5.70 36839 15 49 2.5
  8 Phosphoglycerate kinase  AAA70267 299 7.53 44914 6 21 2.3
  9 Troponin T, fast skeletal muscle AAB39743 131 9.01 29358 6 31 2.3
10 Creatine kinase M-type  NP031736 114 6.58 43250 5 16 2.2
11 Malate dehydrogenase  AAA39509 313 8.93 36052 11 41 2.1
12 Actin, α skeletal muscle NP001091 136 5.23 42372 10 31 2.1
13 Glycogen phosphorylase NP035354 1047 6.65 97689 25 35 2.0
14 Phosphoglycerate kinase  AAA70267 109 7.53 44914 7 22 2.0
15 Phosphoglycerate mutase 2 NP061358 637 8.65 28983 14 51 2.0
16 Glycogen phosphorylase NP035354 54 6.65 97689 2 4 -2.6
17 α-actinin-3  NP038484 374 5.31 103616 7 9 -2.8
pI, isoelectric point.
Table III. List of muscle-associated proteins with an altered abundance in the flexor digitorum brevis muscle from mdx mice.
   Mascot  Molecular Peptides Sequence  Fold
Spot no. Protein name Accession no. score pI mass (Da) matched coverage (%) change
  1 Troponin I, fast skeletal muscle  NP033431 57 8.65 21518 5 30 3.1
  2 Serpina 1d protein  AAH21850 104 5.18 46140 9 24 2.7
  3 αB-crystallin  NP034094 324 6.76 20056 8 45 2.4
  4 Vimentin  CAA69019 261 4.96 51591 21 50 2.4
  5 Phosphoglycerate mutase 2 NP061358 75 8.65 28983 2 8 2.3
  6 Serpina 1d protein  AAH21850 136 5.18 46140 5 11 2.3
  7 Desmin NP034173 206 5.21 53523 10 32 2.2
  8 Leukocyte elastase inhibitor A NP079705 178 5.85 42722 9 30 2.1
  9 Serpina 1d protein  AAH21850 131 5.18 46140 7 17 2.0
10 Tropomyosin, β chain  NP033442 176 4.66 32933 17 47 2.0
11 Aldolase A, isoform 2 NP001170778 202 8.31 39795 15 48 -2.2
12 Aldolase A, isoform 2 NP001170778 249 8.31 39795 13 40 -2.2
13 Parvalbumin α  NP038673 228 5.02 11923 8 65 -2.3
14 14-3-3 Protein γ  AAC14345 116 4.80 28519 8 38 -2.3
15 Aldolase A, isoform 2 NP001170778 163 8.31 39795 13 40 -2.7
16 Parvalbumin α  NP038673 219 5.02 11923 8 65 -3.0
17 Aldolase A, isoform 2 NP001170778 139 8.31 39795 9 27 -3.1
18 Aldolase A, isoform 2 NP001170778 215 8.31 39795 20 55 -3.3
19 Pro-α-2(I) collagen  CAA41205 51 9.23 130046 2 2 -3.4
pI, isoelectric point.
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Immunoblot analysis of mdx muscle preparations. In order 
to verify key proteomic findings, comparative immunoblot 
analysis was carried out. As shown in Fig. 8, the altered 
abundance of two marker proteins from each analysed muscle 
was confirmed by antibody labelling. Panels A-D were stained 
with an antibody to laminin for control purposes. The extracel-
lular matrix protein exhibited relatively comparable amounts 
in normal vs. dystrophic specimens, with the exception of 
the SOL muscle which showed an increased density in the 
mdx preparations. The reduced concentration of myoglobin 
and increased concentration of collagen in the SOL muscle 
(Fig. 8E and I), the decreased levels of actinin and increased 
concentration of phosphoglycerate kinase in EDL muscle 
(Fig. 8F and J), the lower levels of parvalbumin and higher 
levels of serpina in the FDB muscle (Fig. 8G and K) and the 
reduced expression of parvalbumin and increased concentra-
tion of αB-crystallin in the INT muscle (Fig. 8H and L) was 
verified by immunoblot analysis.
Discussion
The proteomic survey of four subtypes of skeletal muscle, 
i.e., SOL, EDL, FDB and INT muscle, presented in this study 
revealed considerable differences in the extent of protein 
perturbations in distinct muscles of the mdx model of Duchenne 
muscular dystrophy. While 24, 17 and 19 protein species were 
altered in the SOL, EDL and FDB muscles from mdx mice, 
respectively, dystrophin-deficient INT muscle preparations 
showed only alterations in fast TnI, αB-crystallin, the 40 kDa 
protein and parvalbumin. This is an interesting finding from 
a global analysis of protein expression patterns in dystrophi-
nopathy and agrees with the idea that the loss of dystrophin 
and concomitant reduction of associated glycoproteins results 
in considerably different secondary changes and cellular 
adaptations in individual skeletal muscles, despite the fact that 
all contractile mdx tissues exhibit the same primary genetic 
abnormality. Two accompanying observations on INT muscle 
Table IV. List of muscle-associated proteins with an altered abundance in the interosseus muscle from mdx mice.
   Mascot  Molecular Peptides Sequence  Fold
Spot no. Protein name Accession no. score pI mass (Da) matched coverage (%) change
1 Troponin I, fast skeletal muscle NP033431 301 8.65 21518 8 29 4.1
2 Troponin I, fast skeletal muscle NP033431 245 8.65 21518 5 21 3.4
3 αB-crystallin NP034094 421 6.76 20056 9 56 2.2
4 40 kDa Protein 1405340A 164 4.80 32848 3 15 2.1
5 Parvalbumin, α NP038673 400 5.02 11923 7 63 -2.2
pI, isoelectric point.
Figure 6. Fluorescence two-dimensional (2D) gel electrophoretic analysis 
of flexor digitorum brevis muscle from mdx mice. Shown is a representative 
RuBPs-labelled master gel of crude tissue extracts from dystrophic flexor 
digitorum brevis muscle. Protein spots with an age-related change in expres-
sion levels are marked by circles and are numbered 1-19. See Table III for the 
mass spectrometric identification of individual muscle-associated proteins. 
The pH-values of the first dimension gel system and molecular mass standards 
of the second dimension are indicated on the top and on the left of the panels, 
respectively.
Figure 7. Fluorescence two-dimensional (2D) gel electrophoretic analysis of 
interosseus muscle from mdx mice. Shown is a representative RuBPs-labelled 
master gel of crude tissue extracts from dystrophic interosseus muscle. 
Protein spots with an age-related change in expression levels are marked by 
circles and are numbered 1-5. See Table IV for the mass spectrometric iden-
tification of individual muscle-associated proteins. The pH-values of the first 
dimension gel system and molecular mass standards of the second dimension 
are indicated on the top and on the left of the panels, respectively.
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from mdx mice agree with the proteomic analyses. Firstly, the 
number of fibers containing central nuclei was lower in the INT 
compared with the SOL and EDL muscles. This is crucial, since 
central nucleation is regarded as a reliable indicator of recent 
muscle fiber regeneration. Secondly, INT and FDB muscles 
from mdx mice did not show any increase in muscle mass, in 
contrast to the SOL and EDL muscles. Hypertrophy of dystro-
phin-deficient muscles has been observed in some models of 
Duchenne muscular dystrophy, including the mdx mouse (59). 
However, the signaling pathways causing muscle growth have 
not yet been fully elucidated (60,61). Nevertheless, both central 
nucleation and the degree of hypertrophy are in line with a 
less severe impairment of INT, compared with the SOL and 
EDL muscles from mdx mice. Thus, results on the patho-
physiology of dystrophin-deficient muscle should be carefully 
interpreted if they are merely obtained with INT fibers from 
mdx mice (9,47).
Previous proteomic studies of mdx muscle tissues concur 
that the deficiency in the full-length Dp427 isoform of the 
membrane cytoskeletal protein, dystrophin, results in disturbed 
protein expression patterns in contractile tissues (26-36). 
Although earlier studies on mdx muscle proteomics differ 
considerably on the listing of individual proteins involved 
in the molecular pathogenesis of muscular dystrophy (25), it 
is clear that the disintegration of sarcolemmal integrity has 
severe consequences for the overall function of affected muscle 
fibers. Interestingly, severe dystrophic diaphragm muscle 
exhibits extensive alterations in the expression of a large 
number of muscle proteins (29-31,33), while mildly affected 
dystrophic extraocular muscle shows much less alterations in 
its proteome (35). This demonstrates a correlation between the 
pathophysiological phenotype of individual muscles from mdx 
mice and the degree of proteome-wide changes. For example, 
extraocular muscle fibers appear to be naturally protected, 
possibly due to the upregulation of the autosomal dystrophin-
homologue, utrophin Up395 (12). In addition, different 
load-bearing capacities and Ca2+-extrusion systems may render 
certain subtypes of skeletal muscle less susceptible to fibrosis 
and necrosis, despite the lack of dystrophin (12-14,62).
Muscle-associated proteins with an altered abundance in 
mdx tissues are mostly involved in the contraction-relaxation 
cycle, metabolite transport, muscle metabolism and the cellular 
stress response. In the mildly affected dystrophic INT muscle, 
the protein with the most significant increase in expression 
was fast TpI (63), indicating a certain degree of remodeling 
of the regulatory elements of the contractile apparatus (64). 
Other changes in protein expression in the dystrophic INT 
muscle were marginal, compared with the other muscles 
examined. In the dystrophic SOL muscle, various MLCs, such 
as isoforms MLC1/3, MLC2 and MLC3 (65), were shown to 
be upregulated in the dystrophin-deficient fibers. The highly 
complex myosin molecule of the contractile apparatus forms 
a hexameric structure consisting of two MHC heavy chains 
and various MLC light chains (66,67). Various combinations 
of myosin heavy and light chains form a plethora of fiber type-
specific isoforms (68) and the MS-based profiling of contractile 
fibers has shown that the actomyosin apparatus is extremely 
plastic (69). Previous proteomic investigations have demon-
strated that neuromuscular activity has a profound effect on 
myosin, actin, troponin and tropomyosin isoform expression 
patterns (57,70). The drastic changes in the dystrophic SOL 
muscle indicate that the dystrophic phenotype is associated 
Figure 8. Immunoblot analysis of normal vs. dystrophic skeletal muscle. Shown are representative immunoblots with expanded views of antibody-decorated 
protein bands. Lanes 1 and 2, 3 and 4, 5 and 6 and 7 and 8 represent normal wild-type (WT) vs. dystrophic (MDX) preparations from soleus (SOL; A, E and I), 
extensor digitorum longus (EDL; B, F and J), flexor digitorium brevis (FDB; C, G and K) and interosseus (INT; D, H and L) muscles, respectively. Blots were 
labelled with antibodies to (A-D) laminin,  (E) myoglobin,  (F) actinin,  (G and H) parvalbumin,  (I) collagen,  (J) phosphoglycerate kinase, (K) serpina and 
(L) αB-crystallin.
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with considerable remodeling of the contractile apparatus, 
including myosin, myosin binding proteins and troponin.
Interestingly, the atypical GPI-anchored cadherin 13 
protein is increased in dystrophic SOL muscle and may 
stimulate angiogenesis (71). Altered expression levels of gluta-
thione S-transferase, αB-crystallin, ferritin and peroxiredoxin 
indicate increased demands of detoxification, cellular stress 
response, iron storage and anti-oxidant activity in dystrophic 
fibers. Of note, specific isoforms of 14-3-3 proteins are altered 
in muscular dystrophy, which has been previously described 
for various neurodegenerative processes (72). Possible intera-
ctions of 14-3-3 proteins with signaling receptors, kinases and 
phosphatase are disturbed in dystrophic SOL muscle. Reduced 
levels of ATP synthase, myoglobin and malate dehydrogenase 
indicate metabolic disturbances in dystrophic SOL muscle.
Apart from altered levels of contractile elements, such as 
troponin, myosin, actin and actinin in dystrophic EDL muscle, 
which demonstrated alterations in the actomyosin apparatus, 
proteomic analysis revealed a striking increase in the expres-
sion levels of key glycolytic enzymes. MS identified the affected 
cytosolic proteins as triosephosphate isomerase, glyceralde-
hyde-3-phosphate dehydrogenase, phosphoglycerate kinase and 
phosphoglycerate mutase, which are involved in the reversible 
conversion of dihydroxyacetone phosphate and glyceralde-
hyde-3-phosphate, the generation of 1,3-bisphosphoglycerate 
and NADH, the production of ATP and 3-phosphoglycerate 
from ADP and 1,3-bisphosphoglycera te, and the reversible 
conversion of 3-phosphoglycerate into 2-phosphoglycerate, 
respectively (73). The increase in several glycolytic enzymes 
suggests a shift to more anaerobic metabolism. Of note, one 
of the key regulatory enzymes of glycogen and glucose utili-
zation in muscle, glycogen phosphorylase, was also found to 
be increased in contractile mdx tissue. A previous proteomic 
survey of slow-twitching vs. fast-twitching skeletal muscles 
has confirmed that fast muscles exhibit high concentrations 
of enzymes involved in the glycolytic pathway and elevated 
levels of glycogen phospho rylase (74). In addition, the elevated 
expression of lactate dehydrogenase, an enzyme that mediates 
the interconversion of the end product of glycolysis, pyruvate, 
and lactate agrees with a glycolytic shift in dystrophic EDL 
muscle. Skeletal muscles utilise anaerobic glycolysis, usually 
for short to moderate duration activities of high intensity (75); 
thus, a significant increase in glycolytic enzymes indicates an 
increased utilization of the glycolytic pathway in the bioener-
getics of the dystrophin-deficient EDL muscle.
In contrast to dystrophic EDL muscle, the dystrophic 
FDB muscle exhibited a reduced expression in a key 
glycolytic enzyme. The affected enzyme, skeletal muscle 
aldolase, mediates the reversible biochemical breakdown of 
fructose-1,6-biphosphate into dihydroxyacetone phosphate and 
glyceraldehyde-3-phosphate (73). In the gluconeogenic pathway, 
muscle aldolase has been shown to form a complex with 
fructose-1,6-biphosphatase and α-actinin on both sides of the 
Z-line of skeletal muscle fibers. The tight association between 
fructose-1,6-biphosphata se and aldolase is proposed to enable 
efficient substrate channeling between these proteins (76). 
However, many glycolytic enzymes are believed to have a 
multi-functional role in many cell types (77). Thus, changes 
in glycolytic enzymes may affect biological mechanisms other 
than the anaerobic breakdown of glucose in skeletal muscle 
tissues (73). For example, enzymes with a primary glycolytic 
function have been demonstrated to also being involved in 
the regulation of apoptosis, metabolic integration, stimulation 
of cell motility and transcriptional regulation (77). It is thus 
difficult to conclude from changes in one glycolytic enzyme 
whether this relates to distinct metabolic alterations in the 
dystrophic FDB muscle or possibly shows adaptations in a 
glycolysis-unrelated biological mechanism.
Altered expression levels in troponin and tropomyosin, 
and the cytosolic Ca2+-binding protein parvalbumin indicate 
disturbances in the contractile apparatus and ion homeostasis, 
respectively. In analogy to dystrophic SOL muscle, the apparent 
upregulation of the molecular chaperone αB-crystallin in 
dystrophic FDB agrees with the concept of an enhanced cellular 
stress response in muscular dystrophy (30). Interestingly, 
cytoskele tal proteins, such as vimentin and desmin were found 
to be increased in dystrophic muscle, which may be due to 
a compensatory mechanism of dystrophin-lacking fibers that 
try to counteract structural instabilities in the membrane 
cytoskele ton of dystrophic FDB muscle. The increased levels 
of the serpina 1d protein may be the basis of a novel biomarker 
of the dystrophic phenotype.
In conclusion, the comparative proteomic survey of four 
frequently used muscles of the mdx mouse model of Duchenne 
muscular dystrophy, SOL, EDL, FDB and INT muscles, has 
demonstrated that high-resolution 2D gel electrophoresis 
in combination with electrospray ionization MS is highly 
suita ble for investigating muscle subtype-specific alterations 
in the dystrophic skeletal muscle proteome. The differences 
in the number and degree of protein alterations in the anal-
ysed mdx muscles indicate that the INT muscle is much less 
affected than SOL, EDL and FDB muscles. In agreement with 
these findings are the lack of hypertrophy in INT muscles 
of mdx mice and the reduced level of central nucleation 
compared with SOL and EDL. Thus, the evaluation of future 
pharmacological studies or experimental gene therapeutic 
approaches for the treatment of dystrophinopathy should 
take into account that the deficiency in dystrophin does 
not affect all skeletal muscle subtypes in a similar manner. 
The individual histological, biochemical and physiological 
properties of different muscles have to be considered for the 
understanding of secondary abnormalities and adaptations in 
muscular dystrophy.
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